Penumbra, Inc. is a healthcare company focused on interventional therapies. The Company designs, develops, manufactures and markets medical devices. It has a portfolio of products that addresses medical conditions and clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. It focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Neuro Thrombectomy (Ischemic Stroke), Neurovascular Embolization (Brain Aneurysms) and Neurosurgical Tools (Hemorrhagic Stroke). Its peripheral vascular products include Peripheral Vascular Embolization and Peripheral Thrombectomy.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment
- Sub-Industry: N/A
- Symbol: NYSE:PEN
- CUSIP: N/A
- Web: www.penumbrainc.com
Capitalization:- Market Cap: $2.75741 billion
- Outstanding Shares: 33,627,000
Average Prices:- 50 Day Moving Avg: $86.33
- 200 Day Moving Avg: $80.95
- 52 Week Range: $56.05 - $91.00
P/E:- Trailing P/E Ratio: 293.91
- Foreward P/E Ratio: 820.00
- P/E Growth: -32.56
Sales & Book Value:- Annual Revenue: $278.61 million
- Price / Sales: 9.90
- Book Value: $11.11 per share
- Price / Book: 7.38
Profitability:- EBIDTA: ($2,820,000.00)
- Net Margins: -2.31%
- Return on Equity: -2.25%
- Return on Assets: -1.96%
Debt:- Current Ratio: 9.66%
- Quick Ratio: 7.60%
Misc:- Average Volume: 177,100 shs.
- Beta: 0.15
- Short Ratio: 17.55
Frequently Asked Questions for Penumbra (NYSE:PEN)
What is Penumbra's stock symbol?
Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."
How were Penumbra's earnings last quarter?
Penumbra, Inc. (NYSE:PEN) posted its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by $0.04. The company earned $73.21 million during the quarter, compared to analyst estimates of $71.08 million. Penumbra had a negative return on equity of 2.25% and a negative net margin of 2.31%. The business's revenue for the quarter was up 26.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.07 earnings per share. View Penumbra's Earnings History.
Where is Penumbra's stock going? Where will Penumbra's stock price be in 2017?
2 equities research analysts have issued 1 year price targets for Penumbra's shares. Their forecasts range from $94.00 to $96.00. On average, they expect Penumbra's share price to reach $95.00 in the next twelve months. View Analyst Ratings for Penumbra.
Who are some of Penumbra's key competitors?
Some companies that are related to Penumbra include Mednax (MD), Hill-Rom Holdings (HRC), Icon Plc (ICLR), Masimo Corporation (MASI), Charles River Laboratories International (CRL), Mallinckrodt PLC (MNK), PRA Health Sciences (PRAH), Taro Pharmaceutical Industries (TARO), PAREXEL International Corporation (PRXL), Acadia Healthcare Company (ACHC), Hikma Pharmaceuticals Plc (HKMPF), Alere (ALR), Bio-Techne Corp (TECH), Medidata Solutions (MDSO), Exact Sciences Corporation (EXAS), VWR Corporation (VWR), bluebird bio (BLUE) and Akorn (AKRX).
Who are Penumbra's key executives?
Penumbra's management team includes the folowing people:
- Adam Elsesser, Chairman of the Board, President, Chief Executive Officer
- Sridhar Kosaraju, Chief Financial Officer and Head of Strategy
- Daniel Donen Davis, President, North America
- James Pray, President, International
- Robert D. Evans, Executive Vice President, General Counsel, Secretary
- Lynn Rothman, Executive Vice President and Chief Business Officer
- Arani Bose M.D., Executive Director and Chief Innovator
- Harpreet S. Grewal, Independent Director
- Don W. Kassing, Presiding Independent Director
- Bridget O'Rourke, Independent Director
How do I buy Penumbra stock?
Shares of Penumbra can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Penumbra's stock price today?
One share of Penumbra stock can currently be purchased for approximately $82.00.
MarketBeat Community Rating for Penumbra (NYSE PEN)MarketBeat's community ratings are surveys of what our community members think about Penumbra and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Penumbra (NYSE:PEN)Earnings History by Quarter for Penumbra (NYSE PEN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/9/2017 | Q1 2017 | ($0.06) | ($0.10) | $71.08 million | $73.21 million | View | Listen |  |
| 2/28/2017 | Q416 | ($0.09) | ($0.08) | $67.54 million | $73.10 million | View | Listen | |
| 11/3/2016 | Q316 | ($0.08) | ($0.04) | $63.25 million | $67.20 million | View | N/A | |
| 8/9/2016 | Q216 | ($0.07) | $0.01 | $58.18 million | $65.10 million | View | N/A | |
| 5/9/2016 | Q116 | ($0.07) | $0.02 | $53.10 million | $57.90 million | View | N/A | |
| 3/8/2016 | Q415 | ($0.10) | $0.05 | $46.76 million | $54.40 million | View | N/A | |
| 11/12/2015 | Q315 | ($0.15) | $0.03 | $43.00 million | $50.42 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Penumbra (NYSE:PEN)Current Year EPS Consensus Estimate: $-0.16 EPS
Next Year EPS Consensus Estimate: $0.1 EPS
Dividend History for Penumbra (NYSE:PEN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Penumbra (NYSE:PEN)Insider Ownership Percentage: 22.00%
Institutional Ownership Percentage: 68.67%
Insider Trades by Quarter for Penumbra (NYSE:PEN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/18/2017 | Thomas Wilder | Director | Sell | 345 | $86.10 | $29,704.50 | |
| 4/24/2017 | Robert D Evans | EVP | Sell | 10,000 | $85.24 | $852,400.00 | |
| 2/14/2017 | Robert D Evans | EVP | Sell | 5,000 | $75.00 | $375,000.00 | |
| 2/13/2017 | Adam Elsesser | CEO | Sell | 7,700 | $72.21 | $556,017.00 | |
| 2/13/2017 | James Robert Pray | Insider | Sell | 1,700 | $73.04 | $124,168.00 | |
| 2/13/2017 | Sridhar Kosaraju | CFO | Sell | 1,600 | $72.94 | $116,704.00 | |
| 2/10/2017 | James Robert Pray | Insider | Sell | 23,900 | $71.08 | $1,698,812.00 | |
| 2/10/2017 | Sridhar Kosaraju | CFO | Sell | 15,500 | $71.49 | $1,108,095.00 | |
| 2/9/2017 | Arani Bose | Insider | Sell | 22,300 | $70.44 | $1,570,812.00 | |
| 2/9/2017 | Lynn Rothman | EVP | Sell | 2,700 | $70.20 | $189,540.00 | |
| 2/7/2017 | James Robert Pray | Insider | Sell | 4,099 | $69.09 | $283,199.91 | |
| 2/7/2017 | Robert D Evans | EVP | Sell | 1 | $70.00 | $70.00 | |
| 2/6/2017 | Arani Bose | Insider | Sell | 17,100 | $70.01 | $1,197,171.00 | |
| 2/6/2017 | Lynn Rothman | EVP | Sell | 2,886 | $70.41 | $203,203.26 | |
| 2/6/2017 | Sridhar Kosaraju | CFO | Sell | 100 | $70.00 | $7,000.00 | |
| 2/3/2017 | James Robert Pray | Insider | Sell | 15,600 | $70.39 | $1,098,084.00 | |
| 2/3/2017 | Robert D Evans | EVP | Sell | 5,000 | $70.35 | $351,750.00 | |
| 2/3/2017 | Sridhar Kosaraju | CFO | Sell | 7,800 | $70.56 | $550,368.00 | |
| 2/1/2017 | Adam Elsesser | CEO | Sell | 21,400 | $70.98 | $1,518,972.00 | |
| 2/1/2017 | Daniel Donen Davis | Insider | Sell | 7,298 | $71.00 | $518,158.00 | |
| 2/1/2017 | Lynn Rothman | EVP | Sell | 4,414 | $70.99 | $313,349.86 | |
| 1/31/2017 | Adam Elsesser | CEO | Sell | 9,000 | $71.26 | $641,340.00 | |
| 1/31/2017 | Daniel Donen Davis | Insider | Sell | 3,000 | $71.29 | $213,870.00 | |
| 1/31/2017 | Lynn Rothman | EVP | Sell | 1,800 | $71.27 | $128,286.00 | |
| 1/30/2017 | Adam Elsesser | CEO | Sell | 8,200 | $70.72 | $579,904.00 | |
| 1/30/2017 | Daniel Donen Davis | Insider | Sell | 2,698 | $70.71 | $190,775.58 | |
| 1/30/2017 | Lynn Rothman | EVP | Sell | 1,700 | $70.79 | $120,343.00 | |
| 1/27/2017 | Arani Bose | Insider | Sell | 31,500 | $74.12 | $2,334,780.00 | |
| 1/27/2017 | Lynn Rothman | EVP | Sell | 7,000 | $74.24 | $519,680.00 | |
| 1/26/2017 | Don W Kassing | Director | Sell | 3,000 | $74.50 | $223,500.00 | |
| 11/16/2016 | Sridhar Kosaraju | CFO | Sell | 25,000 | $65.07 | $1,626,750.00 | |
| 9/9/2016 | Adam Elsesser | CEO | Sell | 57,200 | $71.07 | $4,065,204.00 | |
| 9/6/2016 | Arani Bose | Insider | Sell | 61,000 | $70.72 | $4,313,920.00 | |
| 9/2/2016 | Robert D Evans | EVP | Sell | 3,100 | $70.10 | $217,310.00 | |
| 8/31/2016 | Adam Elsesser | CEO | Sell | 26,000 | $71.15 | $1,849,900.00 | |
| 8/31/2016 | Robert D Evans | EVP | Sell | 5,300 | $71.17 | $377,201.00 | |
| 8/26/2016 | Adam Elsesser | CEO | Sell | 26,800 | $71.06 | $1,904,408.00 | |
| 8/26/2016 | Robert D Evans | EVP | Sell | 5,300 | $71.03 | $376,459.00 | |
| 8/24/2016 | Adam Elsesser | CEO | Sell | 29,000 | $72.95 | $2,115,550.00 | |
| 8/24/2016 | Robert D Evans | EVP | Sell | 6,300 | $73.00 | $459,900.00 | |
| 5/23/2016 | Robert D Evans | EVP | Sell | 5,000 | $50.52 | $252,600.00 | |
| 5/19/2016 | Don W Kassing | Director | Sell | 3,000 | $48.63 | $145,890.00 | |
| 5/19/2016 | Robert D Evans | EVP | Buy | 1,538 | $25.50 | $39,219.00 | |
| 5/16/2016 | James Robert Pray | Insider | Sell | 32,500 | $48.51 | $1,576,575.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Penumbra (NYSE:PEN)
Latest Headlines for Penumbra (NYSE:PEN)
| Source: |
|
| Date | Headline |
|---|
 | Contrasting Entellus Medical (ENTL) and Penumbra (NYSE:PEN)
www.americanbankingnews.com - July 23 at 7:51 AM |
 | ETFs with exposure to Penumbra, Inc. : July 21, 2017
finance.yahoo.com - July 22 at 7:31 AM |
| Penumbra, Inc. (PEN) Director Sells $29,704.50 in Stock
www.americanbankingnews.com - July 20 at 10:24 PM |
| $77.99 Million in Sales Expected for Penumbra, Inc. (NYSE:PEN) This Quarter
www.americanbankingnews.com - July 15 at 9:44 AM |
| Penumbra, Inc. breached its 50 day moving average in a Bearish Manner : PEN-US : July 14, 2017
finance.yahoo.com - July 15 at 7:24 AM |
| Penumbra, Inc. (NYSE:PEN) Given $89.00 Consensus Price Target by Brokerages
www.americanbankingnews.com - July 15 at 12:44 AM |
| Brokerages Anticipate Penumbra, Inc. (PEN) Will Post Earnings of -$0.05 Per Share
www.americanbankingnews.com - July 13 at 8:13 AM |
| ETFs with exposure to Penumbra, Inc. : July 10, 2017
finance.yahoo.com - July 11 at 6:33 AM |
| Critical Comparison: Tactile Systems Technology (TCMD) & Penumbra (PEN)
www.americanbankingnews.com - July 6 at 7:40 AM |
| Brokerages Expect Penumbra, Inc. (PEN) to Post ($0.05) EPS
www.americanbankingnews.com - June 29 at 12:42 AM |
| Penumbra, Inc. breached its 50 day moving average in a Bearish Manner : PEN-US : June 28, 2017
finance.yahoo.com - June 28 at 4:19 PM |
 | Penumbra (PEN) at 52-Week High: What's Driving the Stock?
www.zacks.com - June 28 at 12:18 AM |
| ETFs with exposure to Penumbra, Inc. : June 26, 2017
finance.yahoo.com - June 27 at 7:12 AM |
| Penumbra, Inc. (PEN) Upgraded at BidaskClub
www.americanbankingnews.com - June 22 at 6:04 PM |
| $77.99 Million in Sales Expected for Penumbra, Inc. (PEN) This Quarter
www.americanbankingnews.com - June 21 at 12:10 PM |
| Penumbra, Inc. (PEN) Expected to Announce Earnings of -$0.05 Per Share
www.americanbankingnews.com - June 19 at 9:00 AM |
| Penumbra, Inc. (PEN) Rating Reiterated by BMO Capital Markets
www.americanbankingnews.com - June 16 at 9:23 PM |
 | BRIEF-Penumbra's voluntary field removal of its 3D revascularization devices will not impact its revenue guidance
www.reuters.com - June 14 at 12:20 AM |
| Zacks: Brokerages Set $89.00 Target Price for Penumbra, Inc. (PEN)
www.americanbankingnews.com - June 13 at 8:33 PM |
| Canaccord Genuity Reiterates Buy Rating for Penumbra, Inc. (PEN)
www.americanbankingnews.com - June 13 at 11:34 AM |
| Penumbra, Inc. breached its 50 day moving average in a Bearish Manner : PEN-US : June 12, 2017
finance.yahoo.com - June 12 at 6:49 PM |
| ETFs with exposure to Penumbra, Inc. : June 12, 2017
finance.yahoo.com - June 12 at 6:48 PM |
| Financial Analysis: Penumbra (PEN) versus Masimo (MASI)
www.americanbankingnews.com - June 9 at 10:46 AM |
| Penumbra, Inc. :PEN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017
finance.yahoo.com - June 6 at 7:59 PM |
| Penumbra, Inc. breached its 50 day moving average in a Bearish Manner : PEN-US : June 1, 2017
finance.yahoo.com - June 1 at 7:59 PM |
| Analysts Set $89.00 Price Target for Penumbra Inc (PEN)
www.americanbankingnews.com - May 26 at 4:50 PM |
| Penumbra, Inc. – Value Analysis (NYSE:PEN) : May 19, 2017
finance.yahoo.com - May 19 at 7:46 PM |
| Penumbra, Inc. breached its 50 day moving average in a Bearish Manner : PEN-US : May 18, 2017
finance.yahoo.com - May 19 at 11:56 AM |
| Post Earnings Coverage as Becton, Dickinson and Co.'s Quarterly Revenue Increased 5.2%; EPS Jumped 12.8%
finance.yahoo.com - May 16 at 9:54 AM |
| Edited Transcript of PEN earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - May 11 at 8:47 AM |
| Penumbra Inc (PEN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - May 11 at 8:26 AM |
| Zacks: Brokerages Set $87.67 Target Price for Penumbra Inc (PEN)
www.americanbankingnews.com - May 10 at 8:44 PM |
| Penumbra Inc (PEN) Posts Quarterly Earnings Results, Misses Estimates By $0.04 EPS
www.americanbankingnews.com - May 10 at 4:16 PM |
| Penumbra (PEN) Q1 Loss Wider than Expected, View Intact
finance.yahoo.com - May 10 at 11:43 AM |
| Penumbra Inc (PEN) Given Buy Rating at BMO Capital Markets
www.americanbankingnews.com - May 10 at 7:36 AM |
 | Penumbra, Inc. Reports First Quarter 2017 Financial Results
www.prnewswire.com - May 9 at 6:45 PM |
 | Penumbra reports 1Q loss
marketbeat.com - May 9 at 5:44 PM |
| Penumbra (PEN) Receives Daily Media Sentiment Score of 0.16
www.americanbankingnews.com - May 8 at 11:45 PM |
 | Form 4 Penumbra Inc For: Apr 28 Filed by: Kosaraju Sridhar
www.streetinsider.com - May 3 at 7:52 PM |
| Penumbra, Inc. to Present at the Bank of America Merrill Lynch 2017 Health Care Conference
finance.yahoo.com - May 3 at 7:52 PM |
| Penumbra (PEN) Earning Somewhat Negative Press Coverage, AlphaOne Reports
www.americanbankingnews.com - May 2 at 9:32 PM |
| -$0.06 Earnings Per Share Expected for Penumbra Inc (PEN) This Quarter
www.americanbankingnews.com - May 1 at 11:02 AM |
| Penumbra (PEN) Receiving Favorable Press Coverage, Report Finds
www.americanbankingnews.com - April 28 at 12:30 AM |
| Form 3 Penumbra Inc For: Apr 21 Filed by: O'Rourke Bridget
www.streetinsider.com - April 26 at 11:08 PM |
| Insider Selling: Penumbra Inc (PEN) EVP Sells 10,000 Shares of Stock
www.americanbankingnews.com - April 26 at 8:22 PM |
| Penumbra, Inc. Schedules First Quarter 2017 Earnings Release and Conference ...
finance.yahoo.com - April 25 at 6:19 PM |
| Penumbra, Inc. Schedules First Quarter 2017 Earnings Release and Conference Call for May 9, 2017 at 4:30 PM Eastern Time
finance.yahoo.com - April 25 at 6:19 PM |
| Penumbra (PEN) Earning Very Favorable Press Coverage, Analysis Shows
www.americanbankingnews.com - April 24 at 12:56 PM |
| BRIEF-Penumbra appoints Bridget O'Rourke to board of directors
www.reuters.com - April 21 at 6:59 PM |
| Penumbra, Inc. Appoints Bridget O'Rourke to its Board of Directors
finance.yahoo.com - April 21 at 6:59 PM |
Penumbra (PEN) Chart for Sunday, July, 23, 2017
